EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 292 (2021) E3S Web Conf., 292 (2021) 03076 References
Open Access
Issue
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
Article Number 03076
Number of page(s) 7
Section Environmental Sustainable Development and Industrial Transformation
DOI https://doi.org/10.1051/e3sconf/202129203076
Published online 09 September 2021
  1. Fei, Z., Yibing, W. & Lidong, W. Research Progress on SARS-CoV-2. CHINESE JOURNAL OF VIROLOGY 37, 422-427 (2021). [Google Scholar]
  2. Yihui, C. & Wu, L. The Clinical Symptoms, Classification and Diagnosis of COVID-19. Genomics and Applied Biology 39, 3904-3907 (2020). [Google Scholar]
  3. Steele, L., Orefuwa, E. & Dickmann, P. Drivers of earlier infectious disease outbreak detection: a systematic literature review. Int J Infect Dis 53, 15-20 (2016). [Google Scholar]
  4. Rui-ping, W. et al. How will early warning threshold of outbreak detection algorithms be influenced by the long-term trend of infectious diseases? Modern Preventive Medicine 46, 1921-1923+1932 (2019). [Google Scholar]
  5. Almubaid, Z. & Al-Mubaid, H. Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2. Gene Rep 23, 101064 (2021). [Google Scholar]
  6. Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382, 727-733 (2020). [Google Scholar]
  7. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565-574 (2020). [Google Scholar]
  8. Forster, P., Forster, L., Renfrew, C. & Forster, M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A 117, 9241-9243 (2020). [Google Scholar]
  9. Wang, R., Hozumi, Y., Yin, C. & Wei, G. W. Mutations on COVID-19 diagnostic targets. Genomics 112, 5204-5213 (2020). [Google Scholar]
  10. Huiyu, Z. et al. Clinical points and experience in nucleic acid testing of SARS-CoV-2. International Journal of Laboratory Medicine 41, 523-526 (2020). [Google Scholar]
  11. Qiang, F., Xiu-yue, Z. & Shi-wen, L. Strategies for risk management of medical staff's occupational exposure to COVID-19. Chinese Journal of Nosocomiology 30, 801-805 (2020). [Google Scholar]
  12. Hualan, A. & Jishu, H. Experience and reflection on collecting pharyngeal swabs in fever clinics during the novel coronavirus pneumonia outbreak. China Rural Health 13, 23-24+27 (2021). [Google Scholar]
  13. Jie, W., Songyu, G., Renxin, Z. & Liang, X. Main detection methods of SARS-CoV-2. Chinese Journal of Comparative Medicine 31, 120-124 (2021). [Google Scholar]
  14. Xiaobo, G. et al. Novel coronavirus with real-time fluorescent RT-PCR nucleic acid detection. Shanxi Medical Journal 49, 264-266 (2020). [Google Scholar]
  15. Kissler, S., Tedijanto, C., Lipsitch, M. & Grad, Y.H. Social distancing strategies for curbing the COVID-19 epidemic. medRxiv, 2020.2003.2022.20041079 (2020). [Google Scholar]
  16. Rahaman, M. A., Islam, M. S., Khan, A. A., Sarker, B. & Mumtaz, A. Understanding “Quarantine,” “Social Distancing,” and “Lockdown” during “COVID-19” Pandemic in Response to Global Health: A Conceptual Review. Open Journal of Social Sciences Vol.08No.10, 23 (2020). [Google Scholar]
  17. Prevention, C.f. D. C. a. Guidance for Wearing Masks, <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html> (2021). [Google Scholar]
  18. Fong, M. W. et al. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-Social Distancing Measures. Emerg Infect Dis 26, 976-984 (2020). [Google Scholar]
  19. Huang, Y. F., Bai, C., He, F., Xie, Y. & Zhou, H. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol Res 158, 104939 (2020). [Google Scholar]
  20. Dong, Y. et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 5, 237 (2020). [PubMed] [Google Scholar]
  21. Hwang, W. et al. Current and prospective computational approaches and challenges for developing COVID-19 vaccines. Advanced Drug Delivery Reviews 172, 249-274 (2021). [Google Scholar]
  22. Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat Rev Immunol 21, 73-82 (2021). [Google Scholar]
  23. Liu, X., Liu, C., Liu, G., Luo, W. & Xia, N. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics 10, 7821-7835 (2020). [Google Scholar]
  24. Li, Y. D. et al. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci 27, 104 (2020). [Google Scholar]
  25. Sharma, O., Sultan, A. A., Ding, H. & Triggle, C. R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol 11, 585354 (2020). [Google Scholar]
  26. Hodgson, S. H. et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 21, e26-e35 (2021). [Google Scholar]
  27. Frederiksen, L. S. F., Zhang, Y., Foged, C. & Thakur, A. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Front Immunol 11, 1817 (2020). [Google Scholar]
  28. Vignesh, R., Shankar, E. M., Velu, V. & Thyagarajan, S. P. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol 11, 586781 (2020). [Google Scholar]
  29. Anderson, R. M., Vegvari, C., Truscott, J. & Collyer, B. S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet 396, 1614-1616 (2020). [Google Scholar]
  30. McKinsey&Company. When will the COVID-19 pandemic end?,<https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/when-will-the-covid-19-pandemic-end> (2021). [Google Scholar]
  31. Junzhi, W. (ed Li Qingyun) (Global Health, Global Health, 2021). [Google Scholar]
  32. Banerji, A. et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract 9, 1423-1437 (2021). [Google Scholar]
  33. Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 383, 2439-2450 (2020). [Google Scholar]
  34. Wang, J., Peng, Y., Xu, H., Cui, Z. & Williams, R. O., 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech 21, 225 (2020). [PubMed] [Google Scholar]
  35. Nojszewska, M., Kalinowska, A., Adamczyk-Sowa, M., Kułakowska, A. & Bartosik-Psujek, H. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurol Neurochir Pol 55, 8-11 (2021). [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.